Aptamers Market Report 2025

The aptamers market size has grown exponentially in recent years. It will grow from $2.65 billion in 2024 to $3.28 billion in 2025 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to need for high-specificity binders, therapeutic potential, rise in personalized medicine, potential for therapeutic areas, antibody alternatives, diagnostic point-of-care (POC) devices.

The aptamers market size is expected to see exponential growth in the next few years. It will grow to $8.03 billion in 2029 at a compound annual growth rate (CAGR) of 25.1%. The growth in the forecast period can be attributed to increasing investment in life sciences, expansion in drug development, growth in cancer research, rapid detection in emergency settings, enhanced aptamer selection techniques, regulatory support. Major trends in the forecast period include advancements in selex technology, increasing applications in diagnostics, investment in aptamer research, technological integration with nanotechnology, awareness and education initiatives.

The rising prevalence of chronic respiratory diseases is projected to drive the growth of the aptamers market in the coming years. Chronic respiratory disease is characterized by the narrowing and swelling of airways, often leading to increased mucus production, which complicates breathing and results in symptoms such as coughing, shortness of breath, and wheezing during exhalation. Aptamers play a critical role in detecting the respiratory syncytial virus (RSV), facilitating early disease identification, and aiding in treatment. For example, a report from the Australian Institute of Health and Welfare in June 2024 noted that chronic obstructive pulmonary disease (COPD) accounted for 3.6% of the total disease burden and 50% of the respiratory condition-related burden in 2023. Additionally, in 2022, COPD was the underlying cause of 7,691 deaths, equating to 29.6 per 100,000 population, and representing 4% of all deaths in Australia. Thus, the increasing incidence of chronic respiratory diseases is significantly contributing to the growth of the aptamers market.

The growing emphasis on personalized medicine is anticipated to significantly boost the aptamers market in the coming years. Personalized medicine involves tailoring medical treatments to the unique characteristics of each patient, taking into account factors such as genetics, lifestyle, and environmental influences to provide more effective and targeted healthcare. In this context, aptamers serve as customizable molecular tools for targeted diagnostics and therapy, enabling precise binding to specific molecules in individual patients. For example, in 2022, the FDA approved 12 new personalized medicines, which has allowed personalized medicines to account for at least a quarter of new drug approvals for each of the past eight years. Furthermore, the FDA expanded indications for existing personalized therapies, approved two new siRNA therapies, issued guidance on gene and cell-based therapies - approving five such therapies - and introduced new diagnostic indications to facilitate targeted treatment decisions for various health conditions. Consequently, the heightened focus on personalized medicine is driving the growth of the aptamers market.

Technological innovations are key trends gaining traction in the aptamers market. Leading companies in this sector are developing new technologies, such as artificial DNA aptamers, which are created using flexible and advanced methods to maintain their competitive edge. For instance, in August 2023, the FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration. Izervay presents a novel option for addressing the progression of geographic atrophy, providing hope to patients affected by this severe form of macular degeneration. This treatment aims to slow the degeneration of retinal cells associated with the condition, representing a significant advancement in vision care.

Prominent players within the aptamers market are spearheading the launch of innovative reagents like Optimer-Fc to tackle challenges prevalent in the immunohistochemistry (IHC) sector. Optimer-Fc represents a groundbreaking reagent designed specifically for automating immunohistochemistry workflows. For instance, in March 2023, UK-based biotech company Aptamer Group plc introduced Optimer-Fc, aimed at revolutionizing automated immunohistochemistry workflows, thereby effectively addressing challenges inherent in the IHC market. The company strategically collaborates with leading IHC firms, conducts meticulous validation of Optimer-Fc's performance, and orchestrates trials in partnership with top-tier pharmaceutical entities. Serving as an alternative to antibodies, Optimer-Fc seamlessly integrates Optimer binders into existing workflows, offering heightened precision and selectivity for disease biomarkers within IHC applications. This innovation assumes significance particularly amid patent expirations for IHC antibodies, presenting a patentable solution to meet evolving market needs.

In a significant development during May 2022, Epicore Biosystems, a US-based digital health and wearable solutions company, executed the acquisition of Eccrine Systems, incorporating its advanced aptamer-based sweat sensing technology into Epicore's array of wearable microfluidic solutions. The acquisition encompasses Eccrine Systems, renowned for its wearable sensor technology and electrochemical aptamer-based technology, enabling the quantification of selected biomarkers within sweat samples. This strategic move bolsters Epicore's sensor technology portfolio, enhancing its capabilities in developing wearable solutions and amplifying its proficiency in leveraging aptamer-based technologies for monitoring targeted biomarkers.

Major companies operating in the aptamers market are Aptamer Group Limited, SomaLogic Inc., Aptamer Sciences Inc., Aptagen LLC, NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies Inc., AMS Biotechnology Ltd., Vivonics Inc., TriLink Biotechnologies LLC, Noxxon Pharma SE, AM Biotechnologies LLC, Raptamer Discovery Group, Kaneka Corporation, Novaptech Inc., Maravai Lifesciences Inc., Bio-Techne Corporation, Creative Biolabs Inc., IBA Lifesciences GmbH, Aptabharat Innovations Pvt. Ltd., Profacgen Biotech Inc., Medi GmbH & Co. KG, Pure Biologics Sp. z o.o., Oak BioSciences Inc., Ophthotech Corporation, Novartis AG, NeoNeuro SAS, CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca PLC, GlyTech Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies Inc., IVERIC bio Inc.

North America was the largest region in the aptamers market in 2024. The regions covered in the aptamers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aptamers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aptamers are short synthetic single-stranded oligonucleotides designed to fold into specific structures and bind to target antigens, which can include proteins, molecules, peptides, cells, and tissues. They serve as molecular recognition tools for their respective targets.

There are various types of aptamers, including DNA aptamers, XNA aptamers, and RNA aptamers. DNA aptamers are specific deoxyribonucleic acid (DNA) oligonucleotides capable of binding with high affinity and specificity to target antigens such as peptides, small molecules, cells, proteins, and tissues. They find applications in the design of drug delivery systems. Technologies like SELEX (Systematic Evolution of Ligands by Exponential Enrichment), X-Aptamer, and MARAS (Mirror-Image Aptamer Reverse Selection) techniques are utilized in therapeutic development, research and development, diagnostics, and other applications. Various end users, including pharmaceutical and biotechnology companies, academic and government research institutes, and diagnostic laboratories, employ aptamers for their diverse applications.

The aptamers market research report is one of a series of new reports that provides aptamers market statistics, including aptamers industry global market size, regional shares, competitors with an aptamers market share, detailed aptamers market segments, market trends, and opportunities, and any further data you may need to thrive in the aptamers industry. This aptamers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aptamers market includes revenues earned by entities by providing RNA profiling and detecting cells, viruses, sugars, and antibodies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.